Study #2023-0416
A phase 1/2 trial of Adagrasib in combination with nab-Sirolimus in patients with advanced solid tumors and non-small cell lung cancer with a KRAS G12C mutation
MD Anderson Study Status
Not Accepting
Treatment Agent
Adagrasib, nab-Sirolimus
Description
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Study phase:
Phase I
Physician name:
Marcelo Vailati Negrao
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-833-559-2966
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.